NVCN
$0.04
Neovasc
NVCN
Earnings Whisper ®
N/A
1st Quarter March 2018
Consensus:  ($0.01)
Revenue:  $1.16 Mil
Wednesday
Jun 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NVCN reports earnings?
Beat
Meet
Miss

Where is NVCN's stock price going from here?
Up
Flat
Down
Stock chart of NVCN
Analysts
Summary of analysts' recommendations for NVCN
Score
Grade
Pivots
Resistance
$0.05
$0.05
$0.05

$0.05

Support
$0.05
$0.04
$0.04
Tweet
Growth
Description
Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Company's products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM) for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Neovasc Inc. is headquartered in Richmond, Canada.
Peers
StrykerBoston ScientificAbbott LaboratoriesBecton, DickinsonBaxter InternationalWatersIntegra LifeSciences Holdings3MResMedIntersect ENT